

Antihormonelle Therapie bei Brustkrebs: die richtige Wahl treffen

J. M. Wenderlein

Literatur:

1. Doege D et al. Age-specific prevalence and determinants of depression in long-term breast cancer survivors compared to female population controls. *Cancer Med* 2020; 9: 8713–21
2. Husby J et al. Pregnancy duration and breast cancer risk. *Nat Commun* 2018; 9: 4255
3. Meier CH & Kraenzin ME. Aromatasehemmer und Osteoporose bei Brustkrebs. *Onkologie* 2007; 4: 27–32
4. Marc C.P. & Hopper J. New role for Tamoxifen in saving high-risk breast cancer patients. *ScienceDaily*. ScienceDaily, 7 August 2013. (www.sciencedaily.com/releases/2013/08/130807094646.htm) Zugegriffen am 03.05.2022
5. King, MC. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. *JAMA* 2001; 286: 2251–6
6. Preiß, Dornoff, Schmieder, Honecker, Claßen (Hrsg.). Taschenbuch Onkologie. Interdisziplinäre Empfehlungen zur Therapie 2014/15, 17. Auflage, W. München: Zuckschwerdt Verlag; 2014
7. Curtis HJ et al. Impact of NICE guidance on tamoxifen prescribing in England 2011–2017: an interrupted time series analysis. *British Journal of Cancer* 2018; 118: 1268–75
8. NICE 2018: Early and locally advanced breast cancer: diagnosis and management
9. NICE 2017: Advanced breast cancer: diagnosis and treatment
10. Mikkola TS et al. Reduced risk of breast cancer mortality in women using postmenopausal hormonotherapy: a Finnish nationwide comparative study. *Menopause* 2016; 23: 1199–203